290 related articles for article (PubMed ID: 14620857)
1. An overview of quantitative PCR assays for biologicals: quality and safety evaluation.
Xu Y; Brorson K
Dev Biol (Basel); 2003; 113():89-98. PubMed ID: 14620857
[TBL] [Abstract][Full Text] [Related]
2. Impact of cell culture process changes on endogenous retrovirus expression.
Brorson K; De Wit C; Hamilton E; Mustafa M; Swann PG; Kiss R; Taticek R; Polastri G; Stein KE; Xu Y
Biotechnol Bioeng; 2002 Nov; 80(3):257-67. PubMed ID: 12226857
[TBL] [Abstract][Full Text] [Related]
3. Practical assay issues with the PERT/PBRT assay: a highly sensitive reverse transcriptase assay.
Chang A; Dusing S
Dev Biol (Basel); 2006; 123():91-7; discussion 119-32. PubMed ID: 16566438
[TBL] [Abstract][Full Text] [Related]
4. Real-time quantitative PCR for retrovirus-like particle quantification in CHO cell culture.
de Wit C; Fautz C; Xu Y
Biologicals; 2000 Sep; 28(3):137-48. PubMed ID: 10964440
[TBL] [Abstract][Full Text] [Related]
5. Viral safety and clearance evaluation--implications for process change and comparability.
Dinowitz M
Dev Biol (Basel); 2002; 109():121-6. PubMed ID: 12434921
[TBL] [Abstract][Full Text] [Related]
6. Human retroviruses and herpesviruses: problems and solutions in safety testing of biologicals.
Onions D; Lees G
Dev Biol Stand; 1991; 75():145-58. PubMed ID: 1794616
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Report of the WHO Study Group on Cell Substrates for the Production of Biologicals, 22-23 April 2009, Bethesda, USA.
Knezevic I; Stacey G; Petricciani J; Sheets R;
Biologicals; 2010 Jan; 38(1):162-9. PubMed ID: 19818645
[TBL] [Abstract][Full Text] [Related]
8. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification.
Shi L; Chen Q; Norling LA; Lau AS; Krejci S; Xu Y
Biotechnol Bioeng; 2004 Sep; 87(7):884-96. PubMed ID: 15334415
[TBL] [Abstract][Full Text] [Related]
9. Broad-range real-time PCR assay for the rapid identification of cell-line contaminants and clinically important mollicute species.
Störmer M; Vollmer T; Henrich B; Kleesiek K; Dreier J
Int J Med Microbiol; 2009 Apr; 299(4):291-300. PubMed ID: 18926769
[TBL] [Abstract][Full Text] [Related]
10. Use of PCR for extranous agent testing in avian vaccines.
Ottiger HP
Dev Biol (Basel); 2002; 111():23-6. PubMed ID: 12678221
[TBL] [Abstract][Full Text] [Related]
11. Development of a PCR method for mycoplasma testing of Chinese hamster ovary cell cultures used in the manufacture of recombinant therapeutic proteins.
Eldering JA; Felten C; Veilleux CA; Potts BJ
Biologicals; 2004 Dec; 32(4):183-93. PubMed ID: 15572100
[TBL] [Abstract][Full Text] [Related]
12. A novel, Q-PCR based approach to measuring endogenous retroviral clearance by capture protein A chromatography.
Zhang M; Lute S; Norling L; Hong C; Safta A; O'Connor D; Bernstein LJ; Wang H; Blank G; Brorson K; Chen Q
Biotechnol Bioeng; 2009 Apr; 102(5):1438-47. PubMed ID: 18988264
[TBL] [Abstract][Full Text] [Related]
13. Risk reduction in biotherapeutic products.
Ill CR; Dehghani H
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
[TBL] [Abstract][Full Text] [Related]
14. A comparison of methods for the estimation of retroviral burden.
Bierley ST; Raineri R; Poiley JA; Morgan EM
Dev Biol Stand; 1996; 88():163-5. PubMed ID: 9119132
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of retroviruses in biologicals manufactured for human use.
Hilfenhaus J; Gregersen JP; Müller H; Nowak T; Pranter W
Dev Biol Stand; 1991; 75():159-69. PubMed ID: 1794617
[TBL] [Abstract][Full Text] [Related]
16. Detection of adventitious viruses in biologicals--a rare occurrence.
Nims RW
Dev Biol (Basel); 2006; 123():153-64; discussion 183-97. PubMed ID: 16566443
[TBL] [Abstract][Full Text] [Related]
17. Process changes and their effect on process evaluation for viral clearance.
Marcus-Sekura C
Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
[TBL] [Abstract][Full Text] [Related]
18. Issues related to harmonization of testing requirements for viral safety.
Hayakawa T
Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
[TBL] [Abstract][Full Text] [Related]
19. Quality of biotechnological products: analysis of the expression construct in cell lines used for production of r-DNA derived protein products. ICH Harmonised Tripartite Guideline.
Dev Biol Stand; 1998; 93():205-8. PubMed ID: 9737397
[No Abstract] [Full Text] [Related]
20. Viral safety of biological products in WHO policy.
Grachev VP
Dev Biol Stand; 1991; 75():241-6. PubMed ID: 1794628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
